ClinicalTrials.gg
Status unknownNCT05157763Updated Dec 15, 2021

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

A Phase 1/2 interventional study of EscharEx 5% (EX-02 formulation) in Superficial Basal Cell Carcinoma and Nodular Basal Cell Carcinoma, sponsored by MediWound Ltd. Status unknown at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-15.

Sponsored by MediWound Ltd · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Planned enrollment
80th of 139
32 · median 40
Started
2021
with 12 others
Phase 1/2
12 of 171
3 open now
Registered
124th of 171
by date

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 80th largest by planned enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2021, is one of 12 in phase 1/2, and was the 124th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma.

In patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.

Read the detailed description

32 patients are planned to be enrolled into the study from 2-4 US sites. This study will be an Open-Label Study where all patients will be treated with the investigational product EX-02.

Enrollment will be conducted in 2 stages. In the first stage, a group of sixteen (16) patients will be enrolled and treated as detailed below for group 1. Safety results from the first group of patients will be evaluated by the sponsor and by the DSMB. Based on the safety results and DSMB recommendations, the second group of patients will include additional 16 patients that will be enrolled and treated, as detailed below for group 2. All patients will undergo complete surgical excision at the end of the 8 weeks post treatment period and will be followed up until complete clearance is confirmed by biopsy and the wound is closed.

Each patient will go through the following periods during the trial:

  1. Screening and enrollment period (up to 2 weeks, visit#1):

    Screening and enrollment duration will be up to 2 weeks and will include the following:

    signing informed consent, recording demographics, medical history and concomitant medications, vital signs, physical examination, lesion photography and assessments, and shave biopsy. Only patients with histologically confirmed BCC can be enrolled and start treatment.

  2. Treatment Period (1-3 weeks, 10-14 visits- visits#2-15)

    Group 1: 16 patients- 8 patients with superficial BCC and 8 patients with nodular BCC will undergo 7 treatment applications, once every other day (2 weeks).

    Group 2: Based on safety results of stage 1 and following DSMB review and recommendations, 16 additional patients (8 patient with superficial BCC and 8 patients with nodular BCC) will undergo 7 daily applications. In case of tolerability issues a rescue therapy of either 7 applications every other day (same as in group 1) or 1 day of drug holiday after which daily treatment will continue, will be allowed as needed.

    In both groups, EX-02 5% will be topically applied on the lesion's surface including a margin of 5-10mm, for 8-12 hours each application. All pre application assessments and applications s will be performed at the clinic. Dressing removal will be completed by the patient (by a family member/caregiver) at the patient's home. Between applications, the lesion will be covered by hydrocolloid dressing (applied by the patient or by a family member/caregiver). The treatment area including the skin around the lesion will be photographed before each application at the clinic and assessment of AEs will be performed by the investigator before application and post dressing removal.

    This period will include 10 on-site visits, 7 visits for pre application assessments and drug application (visits# 2, 4, 6, 8,10, 12, 14) and 3 on-site visits for post dressing removal and assessments. The following three (3) post dressing removal visits will be performed at the clinic: after first application (post dressing removal) (visit#3), after second application (post dressing removal) (visit#5) and after last application (post dressing removal) (Visit#15). Additional 4 visits post dressing removal (visits#7, 9, 11 and 13) are optional and will be completed only if needed per PI discretion. These optional visits, if performed, can be performed either at the clinic or remotely (by an IRB approved HIPAA compliance telecommunication). Local lab tests will be obtained on visits#1(screening) and visit#15.

  3. Post Treatment period (8 weeks, 4 bi-weekly remote or on site visits, visit#16-19):

    Post completion of treatment course, the raw bed and the surrounding skin will be treated toward healing of the skin by Vaseline petrolatum or Aquaphor. Once in 2 weeks the treated area will be photographed, the healing status of the wound and adverse events will be assessed. Assessments on first 3 bi-weekly visits, visit#16- 18 will be performed either on site or remotely (via IRB approved, HIPAA compliance telecommunication), based on physician discretion. The 4th bi-weekly visit i.e. Visit #19 will be performed on site. At the end of the 8 weeks post treatment period, on the 4th bi-weekly visit (visit#19), all patients will undergo complete excision, including a lesion margin of 4-5 mm. The specimen will be sent to dermapathologist for histological clearance examination.

  4. Follow Up (until complete clearance and wound closure is achieved, at least one visit):

During the follow up stage, patients will be followed and treated with standard of care. Follow up visit # 20 will be performed once biopsy results are available (from the excision performed on visit#19). Results will be recorded in the eCRF. In cases that margins are not clear, patients will undergo additional excisional procedure per standard of care. Histological results from any additional procedure will be recorded. In cases that margin are clear but additional procedure for wound closure is required, the procedure will be recorded. AEs will be monitored until complete clearance of margins is histologically confirmed and until wound is assessed as closed (and sutured were removed).

The total duration of the study for each participating subject is approximately 14-17 weeks: Screening periods (1-2 weeks) + Treatment (1-3 weeks) + Follow up post treatment and histopathology 8 weeks post treatment + Follow up post-surgical excision (approximately 4 weeks- until wound closure).

03

Conditions studied

  • Superficial Basal Cell Carcinoma
  • Nodular Basal Cell Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria- Patient level

  1. Male or female greater than age 18,
  2. Patients with one primary superficial or nodular basal cell carcinoma lesion ( confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.
  3. Lesion is present for no longer than 4 years.
  4. Lesion with a diameter of 5-10mm,
  5. Patient and/or legally authorized representative (LAR) understands the nature of the procedure, is able and willing to adhere to the protocol regimen, and able to provide a written prior to any study procedure.

Exclusion Criteria:

Exclusion Criteria- Patient level

  1. Evidence of Gorlin syndrome, neoplastic diseases (except actinic lesions), tumor or tumor with high probability of metastatic spread,
  2. Other malignant cancers (non BCC) of the skin at the lesion's site,
  3. Morphea-type basal cell carcinoma (MBCC) at the lesion's site (per report),
  4. Any signs of infection at the lesion site including purulent discharge, tissue abscess, erysipelas, cellulitis, etc.,
  5. Patients with any dermatological disease in the target lesion site or surrounding area (not including chronic actinic damage in the surrounding area),
  6. History of allergy or atopic disease or a known sensitivity to pineapples, papaya, bromelain or papain, as well as known sensitivity to latex proteins (known as latex-fruit syndrome), bee venom or olive tree pollen,
  7. Patients undergoing renal or peritoneal dialysis,
  8. Any condition that would preclude safe participation in the study, e.g. evidence of significant or unstable cardiovascular, pulmonary, liver, hematological, immunological, or any immediate life threatening condition,
  9. Concurrent acute injury or disease that might compromise the patient's welfare or the participation in the study,
  10. Current (within last 12 months) severe alcohol or drug use disorder
  11. Pregnant women (positive blood or urine pregnancy test) or nursing mothers,
  12. Exposure to intervention within 4 weeks prior to enrolment, or anticipated participation in another investigational drug trial or other intervention trial, while enrolled in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    EscharEx 5%

    The powder of EX-02 (4 g per vial) should be reconstituted with 10 ml water for injection (WFI) to obtain 5% EX-02 gel. The EX-02 powder and the WFI are to be mixed up to 15 min prior to use. EX-02 5% gel will be topically applied in a thick layer of 2-3 mm on the lesion surface including margin of 5-10 mm for 8-12 hours (preferable over-night) and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.

    Drug: EscharEx 5% (EX-02 formulation)

Interventions

  • EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.

    Also known as: EX-02 5%

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent AEs (TEAEs) and serious TEAEs (STEAEs).

    All adverse events (AEs) will be listed. Adverse events records will include notification whether the AE is local and occurs near or in the target lesion. The AEs will be listed as counts and percentages by System Organ Class (SOC), Preferred Term (PT), severity, and time of onset. Serious Adverse Events will be analyzed in the same way as AEs

    Time frame: Through study completion - an average of 16 weeks

  2. Vital signs - proportion of patients with abnormal clinical significant measurements

    Assessed pre 2nd, pre 5th application and post last application

    Time frame: Up to completion of treatment period - up to 5 weeks

  3. Pain assessments- Proportion of patients with clinical significant elevation in NPRS score

    Assesed pre 2nd, pre 5th application and post last application compared with pre 1st application

    Time frame: Up to completion of treatment period - up to 5 weeks

  4. Proportion of subjects discontinuing a treatment due to TEAEs, assessed over the entire course of the treatment.

    This proportion will be calculated, together with its 95% confidence interval based on the binomial distribution.

    Time frame: Up to completion of treatment period - up to 5 weeks

  5. Proportion of subjects that requested to discontinue the treatment

    This will be assessed over the entire course of the treatment and will be calculated, together with its 95% confidence interval based on the binomial distribution

    Time frame: Up to completion of treatment period - up to 5 weeks

Secondary outcomes

  1. Proportion of patients who reached complete histological clearance at the end of the post treatment period.

    biopsy will be taken 8 weeks post completion of treatment. The proportion of patients who reached complete histological clearance at the end of the post treatment period, together with its 95% confidence interval based on the binomial distribution.

    Time frame: Up to 13 weeks

  2. Proportion of patients who reached complete clearance at the end of the post treatment period, as clinically assessed prior to surgical removal.

    The proportion of patients who reached complete histological clearance as assessed by the investigator at the end of the post treatment period, prior to the excisional biopsy, together with its 95% confidence interval based on the binomial distribution.

    Time frame: Up to 13 weeks

07

Study locations

2 of 3 sites recruiting
  • Center for Clinical and Cosmetic Research
    Aventura, Florida 33180, United States
    Recruiting
    • Brian Berman, MD · Contact
    • Brian Berman, MD · Principal investigator
  • Moore Clinical Research, Inc.
    Brandon, Florida 33511, United States
    Not yet recruiting
    • Michael Bland, VP · ContactMBland@MoorCR.com · 813-948-7550
    • Stanley N Katz, MD · Principal investigator
  • Center for Clinical Studies, LTD. LLP
    Webster, Texas 77598, United States
    Recruiting
    • Stephen Tyring, MD · Contactstyring@ccstexas.com · 281-333-2288
    • Stephen Tyring, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2021 (actual). Primary completion is estimated for May 2022, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
Dec 15, 2021
StartActual
Jun 30, 2021
Primary completionEst.
May 2022
CompletionEst.
Jun 2022
Last update
Dec 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05157763
Lead sponsor
MediWound Ltd
Responsible party
Sponsor
First posted
Dec 15, 2021
Start date
Jun 30, 2021
Primary completion
May 2022 (estimated)
Completion
Jun 2022 (estimated)
Last update
Dec 15, 2021

Study contacts

Limor Dinur Klein, PhD
Contact
limord@mediwound.com
972779714000
Keren David, MSc
Contact
kerend@mediwound.com
Lior Rosenberg, Prof.
study director · MediWound Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem bromelain

Start the discussion